Long-Term Outcome and Quality of Life After Biological Aortic Valve Replacement in Nonelderly Adults

Johannes Petersen; Henry Krogmann; Hermann Reichenspurner; Evaldas Girdauskas

doi:10.1016/j.athoracsur.2020.04.097

Long-Term Outcome and Quality of Life After Biological Aortic Valve Replacement in Nonelderly Adults

Standard

Long-Term Outcome and Quality of Life After Biological Aortic Valve Replacement in Nonelderly Adults. / Petersen, Johannes; Krogmann, Henry; Reichenspurner, Hermann; Girdauskas, Evaldas.

In: ANN THORAC SURG, Vol. 111, No. 1, 01.2021, p. 142-149.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Petersen, J, Krogmann, H, Reichenspurner, H & Girdauskas, E 2021, 'Long-Term Outcome and Quality of Life After Biological Aortic Valve Replacement in Nonelderly Adults', ANN THORAC SURG, vol. 111, no. 1, pp. 142-149. https://doi.org/10.1016/j.athoracsur.2020.04.097

APA

Petersen, J., Krogmann, H., Reichenspurner, H., & Girdauskas, E. (2021). Long-Term Outcome and Quality of Life After Biological Aortic Valve Replacement in Nonelderly Adults. ANN THORAC SURG, 111(1), 142-149. https://doi.org/10.1016/j.athoracsur.2020.04.097

Vancouver

Petersen J, Krogmann H, Reichenspurner H, Girdauskas E. Long-Term Outcome and Quality of Life After Biological Aortic Valve Replacement in Nonelderly Adults. ANN THORAC SURG. 2021 Jan;111(1):142-149. https://doi.org/10.1016/j.athoracsur.2020.04.097

Bibtex

@article{9252ea0852b44d1080da69fa0883a218,

title = "Long-Term Outcome and Quality of Life After Biological Aortic Valve Replacement in Nonelderly Adults",

abstract = "BACKGROUND: Aortic valve replacement (AVR) is a standard of care in the treatment of aortic stenosis. The aim of the study was to evaluate the long-term outcome and quality of life (QoL) after biological AVR in patients younger than 60 years of age.METHODS: A total of 354 consecutive patients less than or equal to 60 years who underwent biological AVR at our institution (2005-2015) were included. The primary endpoint was actual freedom from AV reintervention, and secondary endpoints were actual freedom from major adverse cardiac and cerebrovascular events (MACCE) as well as mental and physical QoL.RESULTS: Mean age was 52.3 ± 7.1 years and mean follow-up duration was 78.7 ± 38.1 months. Overall survival at 5, 10, and 12 years was 87.6%, 76.3%, and 63.5%, and actual freedom from AV reintervention was 85.5%, 67.8%, and 52.9%, respectively. Actual freedom from MACCE was 82.8%, 63.2%, and 50.4%, respectively. Cox regression revealed concomitant coronary artery disease (P < .001) and creatinine at baseline (P < .001) as independent predictors of survival, AV reintervention, and MACCE. Physical QoL was similar (P = .427) and mental QoL (P = .005) was significantly better compared with the published age-matched control subjects.CONCLUSIONS: Biological AVR in patients less than or equal to 60 years of age is associated with a significant occurrence of actual AV reintervention and MACCE at 10 to 12 years. Mental QoL after biological AVR was superior compared with healthy control subjects. The effect of the most recently developed bioprosthesis, specifically for younger patients, needs to be evaluated. Therefore, a shared decision-making process in prosthetic AV selection is mandatory in AVR patients less than or equal to 60 years of age.",

keywords = "Aortic Valve/surgery, Aortic Valve Stenosis/surgery, Bioprosthesis, Female, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Humans, Male, Middle Aged, Prosthesis Design, Quality of Life, Retrospective Studies, Time Factors, Treatment Outcome",

author = "Johannes Petersen and Henry Krogmann and Hermann Reichenspurner and Evaldas Girdauskas",

year = "2021",

month = jan,

doi = "10.1016/j.athoracsur.2020.04.097",

language = "English",

volume = "111",

pages = "142--149",

journal = "ANN THORAC SURG",

issn = "0003-4975",

publisher = "Elsevier USA",

number = "1",

}

RIS

TY - JOUR

T1 - Long-Term Outcome and Quality of Life After Biological Aortic Valve Replacement in Nonelderly Adults

AU - Petersen, Johannes

AU - Krogmann, Henry

AU - Reichenspurner, Hermann

AU - Girdauskas, Evaldas

PY - 2021/1

Y1 - 2021/1

N2 - BACKGROUND: Aortic valve replacement (AVR) is a standard of care in the treatment of aortic stenosis. The aim of the study was to evaluate the long-term outcome and quality of life (QoL) after biological AVR in patients younger than 60 years of age.METHODS: A total of 354 consecutive patients less than or equal to 60 years who underwent biological AVR at our institution (2005-2015) were included. The primary endpoint was actual freedom from AV reintervention, and secondary endpoints were actual freedom from major adverse cardiac and cerebrovascular events (MACCE) as well as mental and physical QoL.RESULTS: Mean age was 52.3 ± 7.1 years and mean follow-up duration was 78.7 ± 38.1 months. Overall survival at 5, 10, and 12 years was 87.6%, 76.3%, and 63.5%, and actual freedom from AV reintervention was 85.5%, 67.8%, and 52.9%, respectively. Actual freedom from MACCE was 82.8%, 63.2%, and 50.4%, respectively. Cox regression revealed concomitant coronary artery disease (P < .001) and creatinine at baseline (P < .001) as independent predictors of survival, AV reintervention, and MACCE. Physical QoL was similar (P = .427) and mental QoL (P = .005) was significantly better compared with the published age-matched control subjects.CONCLUSIONS: Biological AVR in patients less than or equal to 60 years of age is associated with a significant occurrence of actual AV reintervention and MACCE at 10 to 12 years. Mental QoL after biological AVR was superior compared with healthy control subjects. The effect of the most recently developed bioprosthesis, specifically for younger patients, needs to be evaluated. Therefore, a shared decision-making process in prosthetic AV selection is mandatory in AVR patients less than or equal to 60 years of age.

AB - BACKGROUND: Aortic valve replacement (AVR) is a standard of care in the treatment of aortic stenosis. The aim of the study was to evaluate the long-term outcome and quality of life (QoL) after biological AVR in patients younger than 60 years of age.METHODS: A total of 354 consecutive patients less than or equal to 60 years who underwent biological AVR at our institution (2005-2015) were included. The primary endpoint was actual freedom from AV reintervention, and secondary endpoints were actual freedom from major adverse cardiac and cerebrovascular events (MACCE) as well as mental and physical QoL.RESULTS: Mean age was 52.3 ± 7.1 years and mean follow-up duration was 78.7 ± 38.1 months. Overall survival at 5, 10, and 12 years was 87.6%, 76.3%, and 63.5%, and actual freedom from AV reintervention was 85.5%, 67.8%, and 52.9%, respectively. Actual freedom from MACCE was 82.8%, 63.2%, and 50.4%, respectively. Cox regression revealed concomitant coronary artery disease (P < .001) and creatinine at baseline (P < .001) as independent predictors of survival, AV reintervention, and MACCE. Physical QoL was similar (P = .427) and mental QoL (P = .005) was significantly better compared with the published age-matched control subjects.CONCLUSIONS: Biological AVR in patients less than or equal to 60 years of age is associated with a significant occurrence of actual AV reintervention and MACCE at 10 to 12 years. Mental QoL after biological AVR was superior compared with healthy control subjects. The effect of the most recently developed bioprosthesis, specifically for younger patients, needs to be evaluated. Therefore, a shared decision-making process in prosthetic AV selection is mandatory in AVR patients less than or equal to 60 years of age.

KW - Aortic Valve/surgery

KW - Aortic Valve Stenosis/surgery

KW - Bioprosthesis

KW - Female

KW - Heart Valve Prosthesis

KW - Heart Valve Prosthesis Implantation

KW - Humans

KW - Male

KW - Middle Aged

KW - Prosthesis Design

KW - Quality of Life

KW - Retrospective Studies

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1016/j.athoracsur.2020.04.097

DO - 10.1016/j.athoracsur.2020.04.097

M3 - SCORING: Journal article

C2 - 32526161

VL - 111

SP - 142

EP - 149

JO - ANN THORAC SURG

JF - ANN THORAC SURG

SN - 0003-4975

IS - 1

ER -